abstract |
Compositions and methods for making and using anti-SARS-CoV-2 Spike glycoprotein S1 agents, for example, monoclonal antibodies, SARS-CoV-2 Spike glycoprotein S1-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-SARS-CoV-2 Spike glycoprotein S1 agents, and methods of making and using the same. |